

Decision number: TPE-D-0000002611-83-08/F

Helsinki, 5 June 2013

DECISION ON A TESTING PROPOSAL SET OUT IN A REGISTRATION PURSUANT TO ARTICLE 40(3) OF REGULATION (EC) NO 1907/2006

For (Z)-docos-13-enamide, CAS No 112-84-5, registration number: [REDACTED]

Addressee: [REDACTED]

The European Chemicals Agency (ECHA) has taken the following decision in accordance with the procedure set out in Articles 50 and 51 of Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH Regulation).

I. Procedure

Pursuant to Article 40(1) of the REACH Regulation, ECHA has examined the following testing proposals submitted as part of the registration dossier in accordance with Articles 10(a)(ix) and 12(1)(e) thereof for (Z)-docos-13-enamide, CAS No 112-84-5, by [REDACTED] (Registrant).

- 90-day repeated dose study (OECD Guideline 408 (repeated-dose 90-day oral toxicity in rodents));
- Developmental toxicity study in rats (OECD 414) is tentatively proposed. "Alternative protocols that would allow a scientifically valid assessment of potential developmental hazards along with other endpoints will be considered."

This decision is based on the registration dossier as submitted with submission number [REDACTED], for the tonnage band of 1000 tonnes or more per year. This decision does not take into account any updates after 18 January 2013, the date upon which ECHA notified its draft decision to the Competent Authorities of the Member States pursuant to Article 51(1) of the REACH Regulation.

On 2 November 2010, pursuant to Article 40(1) of the REACH Regulation, ECHA initiated the examination of the testing proposals set out by the Registrant in the registration dossier for the substance mentioned above.

ECHA held a third party consultation for the testing proposals from 16 August 2011 until 30 September 2011. ECHA did receive information from third parties (see section III below).

On 30 October 2012 ECHA sent the draft decision to the Registrant and invited him to provide comments within 30 days of the receipt of the draft decision.

On 2 November 2012 ECHA received comments from the Registrant agreeing to ECHA's draft decision.

On 18 January 2013 ECHA notified the Competent Authorities of the Member States of its draft decision and invited them pursuant to Article 51(1) of the REACH Regulation to submit proposals to amend the draft decision within 30 days of the receipt of the notification. Subsequently, one Competent Authority of a Member State submitted a proposal for

amendment to the draft decision.

On 21 February 2013 ECHA notified the Registrant of the proposal for amendment to the draft decision and invited him pursuant to Article 51(5) of the REACH Regulation to provide comments on the proposal for amendment within 30 days of the receipt of the notification.

ECHA reviewed the proposal for amendment received and decided not to amend the draft decision.

On 21 February 2013 the Registrant provided comments on the proposed amendment.

On 4 March 2013 ECHA referred the draft decision to the Member State Committee.

The Member State Committee took the comments of the Registrant into account. A unanimous agreement of the Member State Committee on the draft decision was reached on 8 April 2013 in a written procedure launched on 27 March 2013. ECHA took the decision pursuant to Article 51(6) of the REACH Regulation.

This decision does not imply that the information provided by the Registrant in his registration dossier is in compliance with the REACH requirements. The decision does not prevent ECHA from initiating a compliance check on the present dossier at a later stage.

II. Testing required

The Registrant shall carry out the following proposed tests pursuant to Article 40(3)(a) of the REACH Regulation using the indicated test methods:

1. Sub-chronic toxicity study (90-day) in rats, oral route (Annex IX, 8.6.2.; test method: EU B.26/OECD 408), and
2. Pre-natal developmental toxicity study in rats or rabbits, oral route (Annex IX, 8.7.2.; test method: EU B.31/OECD 414)

The Registrant shall determine the appropriate order of the studies taking into account the possible outcome and considering the possibilities for adaptations of the standard information requirements according to column 1 or 2 provisions of the relevant Annexes of the REACH Regulation.

Pursuant to Articles 40(4) and 22 of the REACH Regulation, the Registrant shall submit to ECHA by **5 June 2015** an update of the registration dossier containing the information required by this decision.

Data from a second pre-natal developmental toxicity study on another species is a standard information requirement according to Annex X, 8.7.2 of the REACH Regulation. The Registrant should firstly take into account the outcome of the pre-natal developmental toxicity on a first species and all other relevant available data to determine if the conditions are met for adaptations according to Annex X, 8.7 column 2, or according to Annex XI. If the Registrant considers that testing is necessary to fulfill this information requirement, he should include in the update of his dossier a testing proposal for a pre-natal developmental toxicity study on a second species.

At any time, the Registrant shall take into account that there may be an obligation to make every effort to agree on sharing of information and costs with other Registrants.

III. Statement of reasons

The decision of ECHA is based on the examination of the testing proposals submitted by the Registrant for the registered substance and scientific information submitted by third parties.

1. Sub-chronic toxicity study (90-day)

a) Examination of the testing proposal

Pursuant to Article 40(3)(a) of the REACH Regulation, ECHA may require the Registrant to carry out the proposed test.

A sub-chronic toxicity study (90 day) is a standard information requirement as laid down in Annex IX, section 8.6.2 of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

The Registrant proposed testing by the oral route. In the light of the physico-chemical properties of the substance and the information provided on the uses and human exposure, ECHA considers that testing by the oral route is appropriate.

The Registrant proposed to perform the test according to the test method OECD 408. According to the test method EU B.26/OECD 408 the rat is the preferred rodent species. ECHA considers this species as being appropriate.

b) Consideration of the information received during third party consultation

ECHA received third party information concerning the testing proposal during the third party consultation. For the reasons explained further below the information provided by third parties is not sufficient to fulfil this information requirement.

A third party has provided comments on adaptations of information requirements according to Annex IX/X and Annex XI of Regulation (EC) No 1907/2006, regarding OECD Guideline 408 and 414 which have been proposed for the registered substance. However, third parties were invited, as specified by Article 40(2) of the REACH Regulation to submit "scientifically valid information and studies that address the relevant substance and hazard end-point, added used by the testing proposal". As the comments on adaptation of information requirements as such cannot be regarded as information or studies, ECHA concludes that this is not a sufficient basis to fulfil the data/information requirement.

c) Outcome

Therefore, pursuant to Article 40(3)(a) of the REACH Regulation, the Registrant is required to carry out the proposed study: Sub-chronic toxicity study (90-day) in rats, oral route (test method: EU B.26/OECD 408) using the registered substance.

2. Pre-natal developmental toxicity

a) Examination of the testing proposal

Pursuant to Article 40(3)(a) of the REACH Regulation, ECHA may require the Registrant to carry out the proposed test.

Pre-natal developmental toxicity studies are part of the standard information requirements as laid down in Annexes IX and X, section 8.7.2 of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

The Registrant indicated that "alternative protocols that would allow a scientifically valid assessment of potential developmental hazards along with other endpoints will be considered". In the absence of additional information on these alternative protocols, ECHA considered that the test method OECD 414 referred to by the Registrant in section 7.8.2 of the IUCLID dossier and section 5.9.3 of the Chemical Safety Report constitutes the proposed test method.

The Registrant proposed testing by the oral route in the rat. According to the test method EU B.31/OECD 414, the rat is the preferred rodent species, the rabbit the preferred non-rodent species and the test substance is usually administered orally. ECHA considers these default parameters appropriate and testing should be performed by the oral route with the rat or the rabbit as a first species to be used

b) Consideration of the information received during third party consultation

ECHA received third party information concerning the testing proposal during the third party consultation. For the reasons explained further below the information provided by third parties is not sufficient to fulfil this information requirement.

A third party has provided comments on adaptations of information requirements according to Annex IX/X and Annex XI of Regulation (EC) No 1907/2006, regarding OECD Guideline 408 and 414 which have been proposed for the registered substance. However, third parties were invited, as specified by Article 40(2) of the REACH Regulation to submit "scientifically valid information and studies that address the relevant substance and hazard end-point, addressed by the testing proposal". As the comments on adaptation of information requirements as such cannot be regarded as information or studies, ECHA concludes that this is not a sufficient basis to fulfil the data/information requirement.

c) Outcome

Therefore, pursuant to Article 40(3)(a) of the REACH Regulation, the Registrant is required to carry out the proposed study: Pre-natal developmental toxicity study in rats or rabbits, oral route (test method: EU B.31/OECD 414) using the registered substance.

When considering the need for a testing proposal for a prenatal developmental toxicity study in a second species, the Registrant should take into account the outcome of the pre-natal developmental toxicity study on the first species and all available data to determine if the conditions are met for adaptations according to Annex X, 8.7. column 2, or according to Annex XI; for example if the substance meets the criteria for classification as toxic for reproduction Category 1B: May damage the unborn child (H360D), and the available data are adequate to support a robust risk assessment, or alternatively, if Weight of Evidence assessment of all relevant available data provides scientific justification that the study in a second species is not needed.

IV. Adequate identification of the composition of the tested material

The process of evaluation of testing proposals set out in Article 40 of the REACH Regulation aims at ensuring that the new studies meet real information needs. Within this context, the Registrant's dossier was sufficient to confirm the identity of the substance to the extent necessary for evaluation of the testing proposal.

In relation to the proposed tests, the sample of substance used for the new studies must be suitable for use by all the joint registrants. Hence, the sample should have a composition that is within the specifications of the substance composition that are given by the joint registrants. It is the responsibility of all joint registrants of the same substance to agree to the tests proposed (as applicable to their tonnage level) and to document the necessary information on their substance composition.

In addition, it is important to ensure that the particular sample of substance tested in the new studies is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured by each registrant. If the registration of the substance by any registrant covers different grades, the sample used for the new studies must be suitable to assess these grades.

Finally there must be adequate information on substance identity for the sample tested and the grades registered to enable the relevance of the studies to be assessed.

V. General requirements for the generation of information and Good Laboratory Practice

ECHA reminds registrants of the requirements of Article 13(4) of the REACH Regulation that ecotoxicological and toxicological tests and analyses shall be carried out in compliance with the principles of good laboratory practice (GLP).

According to Article 13(3) of the REACH Regulation, tests that are required to generate information on intrinsic properties of substances shall be conducted in accordance with the test methods laid down in a Commission Regulation or in accordance with other international test methods recognised by the Commission or the European Chemicals Agency as being appropriate. Thus, the Registrant shall refer to Commission Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 as adapted to technical progress or to other international test methods recognised as being appropriate and use the applicable test methods to generate the information on the endpoints indicated above.

VI. Information on right to appeal

An appeal may be brought against this decision to the Board of Appeal of ECHA under Article 51(8) of the REACH Regulation. Such appeal shall be lodged within three months of receiving notification of this decision. Further information on the appeal procedure can be found on the ECHA's internet page at http://echa.europa.eu/appeals/app_procedure_en.asp. The notice of appeal will be deemed to be filed only when the appeal fee has been paid.



Jukka Malm
Director of Regulatory Affairs